Novacyt S.A.: Executive Management and Proposed Board Changes
05 Janeiro 2021 - 4:00AM
Business Wire
Regulatory News:
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt" or the
"Company" or the "Group"), an international specialist in clinical
diagnostics, announces that James McCarthy has been appointed as
Chief Financial Officer (CFO), whilst Anthony Dyer has taken on a
new role as Chief Corporate Development Officer (CCDO). Both
appointments are with immediate effect.
Mr McCarthy will become a Board Director of the Company, subject
to shareholder approval, at the AGM. Anthony Dyer will remain a
Board Director until James McCarthy is elected to the Board.
James has held a number of senior positions in major listed and
private equity-backed businesses. Most recently he was CFO of Flint
Group, a $2.5bn revenue, PE backed business with 7,900 staff and
180 sites across 40 countries. Previously, he was CFO of Brambles
Plc’s EMEA CHEP business before being promoted to President of
CHEP’s European team. Brambles Plc is an Australian-based, ASX
listed business with a market capitalisation of AU$16bn. James
trained as an accountant with Dairygold, receiving his ACCA
qualification in 1988, before going on to work for a range of
businesses including Unilever and ICI Plc.
Graham Mullis, Chief Executive Officer of Novacyt,
commented: "On behalf of the Board, I am pleased to welcome
James to the role of CFO. He joins Novacyt having held senior
finance positions at a number of large blue-chip manufacturing
organisations. His considerable financial, commercial and Board
experience will be invaluable as Novacyt embarks on its next stage
of growth.
“I would also like to take this opportunity to thank Anthony
personally for the key role he has played in helping transform
Novacyt into a leading diagnostics developer and manufacturer. His
new, important role reflects the Company’s growth strategy, which
includes selective potential M&A to supplement organic growth
initiatives. I look forward to working with Anthony and James as
part of an expanded executive team.”
The information required by Rule 17 and paragraph (g) of
Schedule 2 of the AIM Rules for Companies in relation to the
appointment of James Martin McCarthy (age 54) is as follows:
Current directorships
Past directorships held within last
five years
Energy Transition Forum Limited
CHEP Israel Limited
Focus4Value Limited
Xeikon NV.
XBC BV
Mr McCarthy holds 10,000 ordinary shares in the Company. There
are no other disclosures required in accordance with Schedule 2(g)
of the AIM Rules.
About Novacyt Group The Novacyt Group is an international
diagnostics business generating an increasing portfolio of in vitro
and molecular diagnostic tests. Its core strengths lie in
diagnostics product development, commercialisation, contract design
and manufacturing. The Company's lead business units comprise of
Primerdesign and Lab21 Products, supplying an extensive range of
high-quality assays and reagents worldwide. The Group directly
serves microbiology, haematology and serology markets as do its
global partners, which include major corporates.
For more information please refer to the website:
www.novacyt.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210104005730/en/
Novacyt SA Graham Mullis, Chief Executive Officer Steve
Gibson, Group Finance Director +44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker) Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470
0470
Numis Securities Limited (Joint Broker) Freddie Barnfield
/ James Black +44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor) Rémi Durgetto /
Yannick Petit +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com /
y.petit@allegrafinance.com
FTI Consulting (International) Victoria Foster Mitchell /
Alex Shaw / Mary Whittow +44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
alex.shaw@fticonsulting.com / mary.whittow@fticonsulting.com
FTI Consulting (France) Arnaud de Cheffontaines +33
(0)147 03 69 48 arnaud.decheffontaines@fticonsulting.com
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
